Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121770 · ClinicalTrials.gov registry record · Phase 1
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
A Phase 1 study of Renal Insufficiency, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01121770: Completed Phase 1 study of Renal Insufficiency, sponsored by Duke University.
NCT01121770 is a Phase 1 study of Renal Insufficiency that has completed, run by Duke University. The registered enrollment target is 9 participants, below the 101-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01121770, a Phase 1 study of Renal Insufficiency, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Primary Outcome
peak level will be collected 2-3 hours after the dose interval level will be collected between peak and midpoint midpoint level will be collected 12 hours after the dose interval level will be collected midpoint and trough trough level will be collected just prior to the next scheduled dose
Conditions Studied
Interventions
- DRUG fondaparinux sodium injection
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01121770 record still lists
NCT01121770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 101-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which fondaparinux sodium injection is the first listed.
NCT01121770 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01121770 about?
NCT01121770 is a clinical study titled ""Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"". The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
What is the current status of trial NCT01121770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-05. Estimated completion is 2013-02.
What conditions does trial NCT01121770 study?
This clinical trial studies the following conditions: Renal Insufficiency.
What interventions are being tested in trial NCT01121770?
The interventions under investigation include: fondaparinux sodium injection (DRUG).
Who is sponsoring clinical trial NCT01121770?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01121770 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01121770's enrollment target sits among peer trials
9 23rd of 22 the lowest of 22 other Renal Insufficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
COMPLETED · Phase 1
-
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia